Hexima (ASX:HXL) EPS (Basic) : A$-0.00 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hexima EPS (Basic)?

Hexima's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was A$-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00.

Hexima's EPS (Diluted) for the six months ended in Dec. 2023 was A$-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00.

Hexima's EPS without NRI for the six months ended in Dec. 2023 was A$-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Hexima's highest 3-Year average EPS without NRI Growth Rate was 24.90% per year. The lowest was 5.00% per year. And the median was 14.95% per year.

Hexima EPS (Basic) Historical Data

The historical data trend for Hexima's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima EPS (Basic) Chart

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

EPS (Basic)

Get a 7-Day Free Trial

-0.08

-0.06

-0.07

-0.01

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial										-0.03	-0.04	-0.01	-	-

Hexima EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hexima's Basic EPS for the fiscal year that ended in Jun. 2023 is calculated as

Basic EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.919	-	0)	/	167.040
	=	-0.01

Hexima's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.385	-	0)	/	167.040
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00

Hexima (ASX:HXL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hexima EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Hexima's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.